Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.

Apetri A, Crespo R, Juraszek J, Pascual G, Janson R, Zhu X, Zhang H, Keogh E, Holland T, Wadia J, Verveen H, Siregar B, Mrosek M, Taggenbrock R, Ameijde J, Inganäs H, van Winsen M, Koldijk MH, Zuijdgeest D, Borgers M, Dockx K, Stoop EJM, Yu W, Brinkman-van der Linden EC, Ummenthum K, van Kolen K, Mercken M, Steinbacher S, de Marco D, Hoozemans JJ, Wilson IA, Koudstaal W, Goudsmit J.

Acta Neuropathol Commun. 2018 May 31;6(1):43. doi: 10.1186/s40478-018-0543-z.

2.

Immunological memory to hyperphosphorylated tau in asymptomatic individuals.

Pascual G, Wadia JS, Zhu X, Keogh E, Kükrer B, van Ameijde J, Inganäs H, Siregar B, Perdok G, Diefenbach O, Nahar T, Sprengers I, Koldijk MH, der Linden EC, Peferoen LA, Zhang H, Yu W, Li X, Wagner M, Moreno V, Kim J, Costa M, West K, Fulton Z, Chammas L, Luckashenak N, Fletcher L, Holland T, Arnold C, Anthony Williamson R, Hoozemans JJ, Apetri A, Bard F, Wilson IA, Koudstaal W, Goudsmit J.

Acta Neuropathol. 2017 May;133(5):767-783. doi: 10.1007/s00401-017-1705-y. Epub 2017 Mar 24.

3.

HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids.

Cox F, Kwaks T, Brandenburg B, Koldijk MH, Klaren V, Smal B, Korse HJ, Geelen E, Tettero L, Zuijdgeest D, Stoop EJ, Saeland E, Vogels R, Friesen RH, Koudstaal W, Goudsmit J.

Front Immunol. 2016 Sep 29;7:399. eCollection 2016.

4.

Relating influenza virus membrane fusion kinetics to stoichiometry of neutralizing antibodies at the single-particle level.

Otterstrom JJ, Brandenburg B, Koldijk MH, Juraszek J, Tang C, Mashaghi S, Kwaks T, Goudsmit J, Vogels R, Friesen RH, van Oijen AM.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):E5143-8. doi: 10.1073/pnas.1411755111. Epub 2014 Nov 17.

5.

PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.

Sanders BP, Edo-Matas D, Custers JH, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WA, Uytdehaag F, Goudsmit J, Lewis JA, Schuitemaker H.

Vaccine. 2013 Jan 21;31(5):850-6. doi: 10.1016/j.vaccine.2012.10.070. Epub 2012 Oct 30.

PMID:
23123018
6.

A highly conserved neutralizing epitope on group 2 influenza A viruses.

Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J.

Science. 2011 Aug 12;333(6044):843-50. doi: 10.1126/science.1204839. Epub 2011 Jul 7.

7.

New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.

Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J.

PLoS One. 2010 Feb 8;5(2):e9106. doi: 10.1371/journal.pone.0009106.

8.

Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.

Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, Friesen RH, Goudsmit J.

J Infect Dis. 2009 Dec 15;200(12):1870-3. doi: 10.1086/648378.

PMID:
19911992
9.

A sensitive cell-based assay for the detection of residual infectious West Nile virus.

Koldijk MH, Bogaards JA, Kostense S, de Vocht M, Gijsbers L, Ter Haak M, Ophorst C, Brakenhoff JP, Weverling GJ, Guichoux JY, Uytdehaag F, Lewis J, Goudsmit J, Marzio G.

Vaccine. 2007 Sep 28;25(39-40):6872-81. Epub 2007 Jul 27.

PMID:
17707954
10.

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F.

Vaccine. 2001 Mar 21;19(17-19):2716-21.

PMID:
11257414

Supplemental Content

Loading ...
Support Center